Rapport Therapeutics to Host 2025 Investor and Analyst Day
BOSTON and SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced it will host its inaugural Investor and Analyst Day on Monday, June 2, 2025, in New York City. The event will also be webcast live.
Rapport senior management will review the company's clinical programs, with a focus on the RAP-219 Phase 2a trial in refractory focal epilepsy. The event will also feature a fireside chat with Dr. Jacqueline A. French—a globally recognized leader in epilepsy research, professor of Neurology at NYU Langone's Comprehensive Epilepsy Center, founder and director of the Epilepsy Study Consortium, and principal investigator of the RAP-219 Phase 2a trial.
Event Details:Date: Monday, June 2, 2025Time: 3:00 – 5:00 p.m. Eastern TimeLocation: Nasdaq MarketSite, New York City
Live and archived webcasts of the presentation can be accessed by visiting 'Events & Presentations' in the Investors section on the Company's website at https://investors.rapportrx.com.
About Rapport TherapeuticsRapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological or psychiatric disorders. The Company's founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport's RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport's precision neuroscience pipeline includes the Company's lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently pursuing RAP-219 as a potential treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
ContactJulie DiCarloHead of Communications & IR, Rapport Therapeuticsjdicarlo@rapportrx.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Analyst Says AMD Stock Can ‘At Least Double' in the Next 12 Months
Michael Lee, the founder of Michael Lee Strategy, said in a recent program on Schwab Network that bearish sentiment has impacted AMD, but the stock remains positioned to benefit from AI in the long term. "I think it's, you know, if you have a 12-month time horizon, you're looking at at least a double from here. I really like the stock and the nature of these AI GPU games is that the demand far exceeds supply, and the problems that Advanced Micro Devices Inc (NASDAQ:AMD) has had is just getting that supply up and running to meet that demand. It's not quite in line with where the street is, and so they have hammered this stock and kind of lost all faith, and there's this overwhelming bearish sentiment that's been ongoing for a while, especially since February on everything AI." Lee said the company could face short-term headwinds amid tariffs and volatility, but it remains a key beneficiary of the technology growth trend. Photo by Kaleidico on Unsplash Advanced Micro Devices (NASDAQ:AMD) bulls believe the market should stop comparing the company's chips with Nvidia and focus on its data-center growth and its competitive edge over other players like Intel. Advanced Micro Devices (NASDAQ:AMD)'s strong growth in the data center segment is indeed impressive, driven by Instinct GPU shipments and strong sales of EPYC CPUs. Advanced Micro Devices (NASDAQ:AMD) will continue to benefit from organic growth catalysts in this segment despite the competition from Nvidia. According to Goldman Sachs Research, global data center demand could surge by 160% by 2030. In the U.S., data centers are projected to use 8% of total power by 2030, up from 3% in 2022. McKinsey estimates that adding the required U.S. capacity will need over $500 billion in infrastructure investment by the decade's end. Artisan Global Opportunities Fund stated the following regarding Advanced Micro Devices, Inc. (NASDAQ:AMD) in its Q4 2024 investor letter: 'Among our top detractors were Advanced Micro Devices, Inc. (NASDAQ:AMD), Novo Nordisk and Danaher. Shares of AMD declined in Q4, which capped off a frustrating year of stock performance that did not seem to match its fundamental progress. Regarding its AI opportunity, the company accomplished everything we had hoped for over the past 18 months. It successfully entered the market with its MI300 graphic processing unit (GPU) chip and raised its latest 2024 AI-related revenue guidance to $5.0 billion from $4.5 billion. However, its shares have experienced weakness for two primary reasons. First is the emergence of custom AI accelerator chip solutions from Broadcom and Marvell (a Q4 buy) as alternatives to the GPU solutions from NVIDIA and AMD. While this competitive threat is more significant than we had initially anticipated, we continue to be excited about AMD's opportunity moving forward. We believe the AI-related market will grow to $400 billion–$500 billion in the next three years (compared to $100 billion in 2024). We expect that NVIDIA's market share will fall from ~90%in2024to60%–80%overthesameperiodasitcedes market share to AMD (from5%in2024to10%–20%) and custom accelerator solutions (from 5% in 2024 to 10%–20%). Under these assumptions, we expect AI GPUs to double AMD's total 2024 sales. Second is cyclical struggles within other areas of its business. While data center revenues have more than doubled over the past two years, the gaming business is down more than 60%, and embedded (specialized chips found in various industrial and consumer products) is down20%.As its data center business continues to grow and the cyclical areas of its business bounce back, we expect AMD to deliver stronger earnings growth.' While we acknowledge the potential of AMD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
HSBC Raises Price Target on Broadcom (AVGO) to $400 From $240, Upgrades it to Buy
Broadcom Inc. (NASDAQ:AVGO) is one of the 13 Best Long Term Growth Stocks to Invest in Right Now. On June 24, HSBC made a notable improvement in its price target for Broadcom Inc. (NASDAQ:AVGO), nearly doubling it from $240 to $400. Analyst Frank Lee upgraded the stock to Buy, expressing bullish sentiments for the company's AI chip revenues and stating that they are likely to 'significantly beat market expectations.' The notable price target hike implies significant potential for Broadcom Inc. (NASDAQ:AVGO) ahead. A technician working at a magnified microscope, developing a new integrated circuit. HSBC was previously less bullish on the stock because of its concerns about Apple's share loss in the wireless segment and wanted better visibility into the Application-Specific Integrated Circuit customer pipeline. The analyst told investors in a research note that it turned bullish on Broadcom Inc. (NASDAQ:AVGO) because it expects its ASIC revenues to considerably exceed market expectations, supported by pricing power and better ASIC project visibility. Broadcom Inc. (NASDAQ:AVGO) is a leading multinational technology company specializing in semiconductor and infrastructure software products. While we acknowledge the potential of AVGO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
PayPal, Big Ten & Big 12 Conferences Partner for Student-Athlete Revenue Sharing
PayPal Holdings Inc. (NASDAQ:PYPL) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 26, PayPal announced multi-year partnerships with the Big Ten and Big 12 Conferences to revolutionize the distribution of institutional payments from universities directly to student-athletes under a new revenue-sharing model. The initiative allows athletic departments to securely and efficiently disburse funds through PayPal. The Big 12's agreement with PayPal is valued at ~$100 million over 5 years, which amounts to ~$1 million per school annually. The collaboration follows a recent court decision permitting colleges and universities to share revenue directly with student-athletes. A consumer in a cafe paying for goods using a mobile payment app. The first phase of the rollout is expected to begin in the summer of 2025, with student-athletes starting to receive these institutional payments via PayPal as early as July 1. PayPal is also set to become a preferred payment partner for tuition payments at select schools and offer students and parents a convenient and flexible payment option starting in early 2026. PayPal Holdings Inc. (NASDAQ:PYPL) is a technology platform that enables digital payments for merchants and consumers worldwide. While we acknowledge the potential of PYPL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
